Praluent

Adult Dosing .

Dosage forms:  INJ (pen): 75 mg per mL, 150 mg per mL

primary hyperlipidemia

[75-150 mg SC q2wk or 300 mg SC q4wk]

Start: 75 mg SC q2wk or 300 mg SC q4wk; Info: may adjust dose to 150 mg SC q2wk after 4wk; see pkg insert for missed dose recommendations

heterozygous familial hypercholesterolemia

[w/o LDL apheresis]

Dose: 75-150 mg SC q2wk or 300 mg SC q4wk; Start: 75 mg SC q2wk or 300 mg SC q4wk; Info: may adjust dose to 150 mg SC q2wk after 4wk; see pkg insert for missed dose recommendations

[w/ LDL apheresis]

Dose: 150 mg SC q2wk; Info: see pkg insert for missed dose recommendations

homozygous familial hypercholesterolemia, adjunct tx

[150 mg SC q2wk]

Info: see pkg insert for missed dose recommendations

cardiovascular event risk reduction

[75-150 mg SC q2wk or 300 mg SC q4wk]

Start: 75 mg SC q2wk or 300 mg SC q4wk; Info: may adjust dose to 150 mg SC q2wk after 4wk; see pkg insert for missed dose recommendations

renal dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

Peds Dosing .

Dosage forms:  INJ (pen): 75 mg per mL, 150 mg per mL

heterozygous familial hypercholesterolemia, adjunct tx

[8 yo and older, <50 kg]

Dose: 150 mg SC q4wk; Info: may adjust dose to 75 mg SC q2wk after 4wk; see pkg insert for missed dose recommendations

[8 yo and older, >50 kg]

Dose: 300 mg SC q4wk; Info: may adjust dose to 150 mg SC q2wk after 4wk; see pkg insert for missed dose recommendations

renal dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined